Major Depression With Psychotic Features Clinical Trial
Official title:
Treatment of Major Depressive Disorder With Psychotic Features With Quetiapine Monotherapy; Quetiapine and Citalopram; or Haloperidol and Citalopram
The purpose of this study is to examine the mood stabilizing and antipsychotic properties of quetiapine in the treatment of depression by comparing subjects who were randomly assigned to either quetiapine monotherapy, quetiapine and citalopram; or haloperidol and citalopram. We hypothesize that quetiapine monotherapy would have similar effects to the combination of a first generation antipsychotic plus an antidepressant for the treatment of a major depressive episode with psychosis.
Status | Terminated |
Enrollment | 60 |
Est. completion date | January 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Male and female subjects between the ages of 18 to 75 years. - A Structured Clinical Interview for the DSM-IV (SCID) derived diagnosis of major depression with psychosis, single or recurrent episode (unipolar or bipolar). - Subjects may have an anxiety disorder or an additional mood disorder such as dysthymia. - Baseline 24-item Hamilton Depression Rating Scale (HDRS) score of greater than or equal to 21. - A baseline Positive and Negative Syndrome Scale (PANSS) score of greater than or equal to 4 on at least one of the 4 psychosis items. - Women of childbearing potential must agree to practice a medically accepted means of contraception. - Length of current episode no longer than 3 months. Exclusion Criteria: - Pregnant or lactating women - Women of child-bearing age who refuse a pregnancy test or who refuse to use a contraceptive technique when sexually active. - Persons with other psychotic disorders; a mood disorder due to a general medical condition or substance-induced; substance dependence disorder in the last 6 months; substance abuse in the last 6 months or a dementing disorder are excluded. - Persons with serious, unstable medical illnesses. - Subjects who have been intolerant or nonresponsive to adequate trials of quetiapine, haloperidol and/or citalopram. - Subjects who have received an injectable decanoate medication within 1 half life of the medication (i.e, 4 weeks for haloperidol or 2 weeks for fluphenazine). - Subjects who have received fluoxetine within 4 weeks prior to randomization. - Subjects who have received aripiprazole within 2 weeks prior to randomization. - Subjects who have been treated with ECT within the last 6 months. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Rush University Medical Center | Chicago, | Illinois |
Lead Sponsor | Collaborator |
---|---|
Rush University Medical Center | AstraZeneca |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hamilton Rating Scale for Depression | |||
Secondary | Positive and Negative Syndrome Scale | |||
Secondary | Young Mania Rating Scale | |||
Secondary | Barnes Akathisia Scale | |||
Secondary | Simpson Angus Scale | |||
Secondary | Clinical Global Impressions |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00174590 -
Treatment of Major Depressive Disorder With Psychotic Features.
|
Phase 3 | |
Completed |
NCT01259427 -
Reducing Internalized Stigma in People With Serious Mental Illness
|
Phase 2 | |
Terminated |
NCT01624831 -
Social Cognition in Longstanding Psychosis
|
||
Recruiting |
NCT05877716 -
EPI-MINN: Targeting Cognition and Motivation - National
|
N/A | |
Recruiting |
NCT04497857 -
Academic-Community EPINET (AC-EPINET)
|
N/A | |
Completed |
NCT01196286 -
Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis
|
N/A | |
Recruiting |
NCT04004416 -
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
|
Phase 4 | |
Completed |
NCT01570972 -
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
|
N/A |